Section 11.8: Miscellaneous Ophthalmic Preparations

Tear Deficiency, Ocular Lubricants, and Astringents
- Hypromellose 0.3% Eye Drops
- Hypromellose 0.3% Single Use Eye Drops
- Carbomer 980 (Polyacrylic Acid) 0.2% Eye Drops (Viscotears, Gel Tears or Clinitas Gel)
- Carbomer 980 (Polyacrylic Acid) 0.2% Single Use Eye Drops (Viscotears)

- Acetylcysteine 5% with Hypromellose 0.35% Eye Drops
- Carmellose 0.5% Eye Drops (Optive)
- Carmellose 0.5% Single Use Eye Drops
- Carmellose 1% Single Use Eye Drops
- Hypromellose 0.3% Eye Drops with Dextran ‘70’ 0.1% (Tears Naturale)
- Hydroxyethylcellulose 0.44% with Sodium Chloride 0.35% Single Use Eye Drops (Artificial Tears)
- Polyvinyl Alcohol 1.4% Eye Drops (Liquifilm or Sno-Tears)
- Polyvinyl Alcohol 1.4% Single Use Eye Drops (Liquifilm)
- Povidone 5% Eye Drops
- Retinol Palmitate 250units/g, White Soft Paraffin, Light Liquid Paraffin, Liquid Paraffin and Wool Fat Eye Ointment (VitA-POS)
- Sodium Hyaluronate 0.1% Eye Drops (Hylo-Tears)
- Sodium Hyaluronate 0.2% Eye Drops (Hylo-Forte)
- White Soft Paraffin 57.3%, Liquid Paraffin 42.5% and Wool Alcohols 0.2% Eye Ointment (Lacri-lube)

Ocular Diagnostic Preparations
- Fluorescein 20% Injection
- Fluorescein 1% Single Use Eye Drops
- Fluorescein 2% Single Use Eye Drops
- Fluorescein Ophthalmic Strips

Ocular Peri-Operative Drugs
- Acetylcholine 1% Eye Drops
- Apraclonidine 0.5% Single Use Eye Drops
- Apraclonidine 1% Single Use Eye Drops
- Balanced Salt Solution
- Balanced Salt Solution Eye Drops
- Diclofenac 0.1% Single Use Eye Drops
Prescribing Guidance:

Local guidance regarding choice of ocular lubricants is available [here](#). Note that with secondary care, available products may differ slightly to provide the most cost effective alternative.

Ranibizumab is a vascular endothelial growth factor inhibitor licensed for the treatment of neovascular (wet) age-related macular degeneration. It is given by intravitreal injection by specialists experienced in the management of this condition.

**NICE guidance (August 2008):**
Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:
- the best corrected visual acuity is between 6/12 and 6/96;
- there is no permanent structural damage to the central fovea;
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension;
- there is evidence of recent disease progression;
- the cost of ranibizumab beyond 14 injections is met by the manufacturer.

Ranibizumab should only be continued in patients who maintain adequate response to therapy.

Items for Restricted Prescribing:

Hydroxypropyl Guar eye drops are reserved for patients with filamentary keratitis

Bromfenac 0.09% eye drops and Nepafenac 1mg/ml eye drops are restricted to post-operative use under the supervision of a consultant ophthalmologist.